The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

e a degludeca (Tresiba). A companhia farmacêutica Biomm, produtora da Glargilin, venceu em 2024 a licitação para o fornecimento de 3,3 milhões de unidades de insulina em caneta ao Ministério ...

Today’s settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba, Fiasp, and Novolin, at any formulation and via any delivery method—at $35 per monthly prescription (3 ...